Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report

doi:10.5527/wjn.v15.i1.116620

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

(37)

(33)

(0)

(1534)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Mar 25, 2026; 15(1): 116620
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.116620

Full Size Figure Download Figure

Figure 1 Medical history timeline of patient remissions and relapses.

Citation: Moura AF, Rocha PN, Moura-Landim D, Moura Jr JA, Moura-Neto JA. Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report. World J Nephrol 2026; 15(1): 116620
URL: https://www.wjgnet.com/2220-6124/full/v15/i1/116620.htm
DOI: https://dx.doi.org/10.5527/wjn.v15.i1.116620

Moura AF, Rocha PN, Moura-Landim D, Moura Jr JA, Moura-Neto JA. Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report. World J Nephrol 2026; 15(1): 116620 [PMID: 41884251 DOI: 10.5527/wjn.v15.i1.116620]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.